Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers November 18, 2017
Pharmacy Choice - Pharmaceutical News - Johnson & Johnson Stops Hepatitis C Drug Development Program [Algeria Press Service] - November 18, 2017

Pharmacy News Article

 9/13/17 - Johnson & Johnson Stops Hepatitis C Drug Development Program [Algeria Press Service]

In the wake of Gileads string of hepatitis C therapy approvals, Johnson & Johnsons pharmaceutical division, Janssen, has announced that it will cease development for the infectious disease. Instead, the company plans to focus on drug development for the chronic hepatitis B market, for which there are far fewer therapies.

According to Janssen, the decision was made in light of the increasing availability of a number of highly effective therapies addressing the medical need in hepatitis C. In July of this year, Gilead received FDA approval for Vosevi, its fourth drug developed to treat hepatitis C.

Specifically, the drugmaker will halt development on JNJ-4178, an investigational combination antiviral drug designed to treat hepatitis C. While the currently-underway Phase II clinical trials for the drug will continue as planned, development of the drug will stop as soon as those programs end.

Going forward, our hepatitis R&D efforts will focus on chronic hepatitis B, where a high unmet medical need still exists, said Dr. Lawrence M. Blatt, Global Therapeutic Area Head, Infectious Disease Therapeutics, Janssen. Our scientists are energized by this challenge and our research ambition is to achieve a functional cure of hepatitis B which affects over a quarter of a billion people globally.

Janssen has a long history of hepatitis C drug development. However, most drugs used to treat the disease have a hard time competing with Gileads over 90 percent cure rate for hepatitis C.

In 2015, Achillion inked a licensing agreement with Janssen for JNJ-4178 which has now been terminated following the companys decision to discontinue development.

We are disappointed by Janssen`s decision to discontinue HCV development given the positive data presented in phase 2a with JNJ-41781, demonstrating a 100% cure rate after only six weeks of therapy," said Dr. Milind Deshpande, President and Chief Executive Officer of Achillion.



(c) APS 2017. All Rights Reserved Provided by SyndiGate Media Inc. (Syndigate.info).

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

LIVE ONLINE CE

Last Chance
Nov 19: Biosimilar Drugs: Legal, Regulatory & Safety Considerations
Nov 20: Obesity Management: Overview of Pharmacotherapy
Nov 21: Standards of Practice for Filling Controlled Substance Prescriptions in Florida
Nov 22: Medical Marijuana: Examining the Science, Not the Politics
Nov 27: Drug Diversion and the Law: Updates and Considerations
Click for entire Webinar Calendar

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Nursing Jobs
Are you a nurse looking for a job?

Check out the Nursing Job Source.

Your number one choice for nursing jobs.



Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415